C-TNMCMitotech
mitochondrial protection, oxidative stress, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-TNMC
C-TNMCC-TNMCmitochondrial protection, oxidative stress, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
00:00:00 Dr. Ilia Stambler (Chairman, Vetek Association. Bar Ilan University) 00:00:40 Prof. Amnon Albek (Rector. Bar-Ilan University) 00:05:52 Prof. Michal Ben-Shachar (Chairperson. The Unit for Interdisciplinary Studies, Bar-Ilan University) 00:11:55 Dr. Noam Yuran (Chairman. Graduate Program in Science, Technology and Society, Bar-Ilan University) 00:17:08 Alex Friedman (Chairman. Disabled, Not Half a Person) 00:22:36 Iris Barner (British Council. Director for Israel) 00:28:50 Hanan Tal (CEO. Vetek Association) 00:34:08 Dr. Ilia Stambler (Chairman, Vetek Association. Bar Ilan University) 00:55:03 Prof. Valery Krizhanovsky (Weizmann Institute of Science) Senescent cells: where to find them and how to deal with them. 01:15:17 Prof. Alon Monsonego (Ben-Gurion University of the Negev) Cellular and molecular trajectories of age-associated lymphocytes and their impact on aging and cognitive decline. 01:41:18 Prof. Carmela R. Abraham (Advantage Therapeutics, Klothea Bio) Increasing K
👀 Visomitin (SkQ-1) 👀 ⬇⬇⬇ SPIS TREŚCI: 0:00 - Wstęp 0:45 - Historia 1:18 - Zastosowanie 2:13 - Potencjał 3:19 - Dawkowanie i sposób podania 3:41 - Bezpieczeństwo 3:52 - Przeciwwskazania 4:03 - Interakcje 4:13 - Skutki uboczne 4:34 - Zakończenie ✅ ŹRÓDŁA: https://www.nature.com/articles/s41598-017-00802-8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660788/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735228/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679790/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393248/ https://pubmed.ncbi.nlm.nih.gov/25519068/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249456/ https://pubmed.ncbi.nlm.nih.gov/26914404/ https://pubmed.ncbi.nlm.nih.gov/29995559/ - Skulachev, Maxim V., „Kompozycja farmaceutyczna do stosowania w okulistyce medycznej i weterynaryjnej”, opublikowana 26.02.2019, przypisana do Mitotech SA. - Antonenko, YN; Roginsky, Wirginia; Pashkovskaya, AA; Rokitskaya, TI; Kotowa, EA; Zaspa, AA; Czerniak, BV; Skulachev, wiceprezes (
The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study | Ophthalmology and Therapy | Springer Nature Link Skip to main content Advertisement Account Menu Find a journal Publish with us Track your research Search Saved research Cart Home Ophthalmology and Therapy Article Repository Corticotropin Injection (Acthar ® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study Original Research Open access Published: 20 October 2021 Vo … d PDF Save article View saved research Ophthalmology and Therapy Aims and scope Submit manuscript Repository Corticotropin Injection (Acthar ® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study Download PDF David Wirta 1 , Eugene McLaurin 2 , George Ousler 3 , Jingyu Liu 4 , R. Oktay Kacmaz 4 & … Joseph Grieco 4 Show authors 3146 Accesses 12 Citations 2 Altmetric Explore all metrics Abstract Introduction N … nocortin receptor agonists. J Recept Signal Transduct Res. 2020:1–9. Decker DA, Grant C, Oh L, Becker PM, Young D, Jordan S. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus. 2014;23(8):802–12. Article CAS Google Scholar Olsen NJ, Decker DA, Higgins P, Becker PM, McAloose CA, Benko AL, et al. Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro. Arthritis Res Ther. 2015;17 … Annual Meeting (May 17–20, 2021). Disclosures David Wirta has received research grant support from Mallinckrodt Pharmaceuticals. Eugene McLaurin has financial relationships with Aldeyra Therapeutics; Allergan; Aurinia Pharmaceuticals; Hanall Biopharma; Mitotech; Ocular Therapeutix; ReGenTree, LLC; Santen Pharmaceutical Co., Ltd.; Shire; Sun Pharma; and TopiVert Ltd. George Ousler has a financial relationship with Mallinckrodt Pharmaceuticals. Jingyu Liu, R. Oktay Kacmaz, and
Dry eye and ocular surface disease... - Ophthalmology Times Facebook Log In Ophthalmology Times's Post Ophthalmology Times November 11, 2025 · Shared with Public Dry eye and ocular surface disease continue to challenge clinicians, particularly as patient populations grow older and systemic comorbidities become more common. To gain insight into how the field is evolving, the Eye Care Network reached out to leading ophthalmologists regarding emerging strategies and technologies shaping modern management. This Q&A explores navigating refractory cases, the promise of new biologic and topi
Mitotech Solutions Ltd | Innovation. Integration. Excellence — Globally
Optometry Today - "Dry eye disease is no longer a niche... Facebook Log In Optometry Today's Post Optometry Today June 12 at 9:54 AM · Shared with Public "Dry eye disease is no longer a niche concern; it is one of the most common and rapidly growing challenges in modern eye care," says Essilor Instruments. Discover more about Espansione from Essilor Instruments and how it can support dry eye management https://ow.ly/a7UE50Z9mLI All reactions: 2 1 comment 1 share Like Comment Most relevant Top fan Kevin Marsh The growing focus from diagnostics to tear film analysis and meibo
Some people are saying the EU AI Act wasn't built for agentic AI. I disagree. And I'm genuinely excited to have co-authored a pre-print (led by Luca Nannini) that explores the the interaction between… | Adam Leon Smith DEng FBCS | 18 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this … Report this comment Time and time again the AI Act‘s approach of regulating the application of AI rather than the technology itself proves to be a wise one. Thanks Luca Nannini and Adam Leon Smith DEng FBCS for connecting breathless technology news cycles to durable principles Like Reply 7 Reactions 8 Reactions Alessandro Stazi 2mo Report this comment I agree. Like Reply 1 Reaction Aoife Whitford Gordon LLM CIPP/E AI Algorithm Auditor 2mo Report this comment Th … ls Lölfing in saying out loud: General Product Safety Regulation (GPSR) doesn't apply to pure software agents that have no connection to tangible items. It doesn't matter that the Commission claimed otherwise in an online FAQ. Law and courts do not care about online FAQs, and the Commission's own Blue Guide — which commands immeasurably higher respect and has actual legal weight — leads us, in conjunction with other factors noted in the paper, to the conclusion that GPSR does … tion with other factors noted in the paper, to the conclusion that GPSR doesn't apply to pure software, so there is a genuine gap in the product safety regime in between the scopes of the AI Act and the GPSR, where the non-high-risk AI agents live. I am not saying it's good, or it's bad, I'm signposting just one of the findings of this paper. We're not the first to flag this particular controversy, but happy to contribute 😀 CRA does address cybersecurity of pure software, an … hestrating everything so that this worked out! And a personal thank you for the proposal to contribute, the reminders, and the consistent feedback. Academic papers are usually where I get stuck as a potential author because of multiple factors (mostly on my side), but somehow you've herded the cats (including this one) — I've made my contribution
Who Attended Targeting Mitochondria 2023? - World Mitochondria Society The Future of Medicine will come through Mitochondria We are excited to invite you to the 17th World Mitochondria Scoiety's Annual Meeting, happening from October 21–23, 2026, in Berlin. This annual event brings together top experts in mitochondrial research and medicine to share new discoveries and ideas in mitochondrial therapy, gene treatment, and mitochondrial transplantation. READ MORE ... Who Attended Targeting Mitochondria 2023? Industries: Stealth Therapeutics (Sponsor) Mitotech (Sponsor) Adjuvi … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
EyeWorld Weekly, January 7, 2022 - EyeWorld Skip to content Search... Submit search Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME Programs & Projects Corporate Replay Corporate Educational Events Supplements Menu Close Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME Pr … S device trial begins Ivantis has begun a pivotal clinical trial for standalone application of its Hydrus Microstent (without concurrent cataract surgery as indicated in its current FDA approval). According to the company’s press release, the first patient has been enrolled in the FRONTIER trial, which will evaluate the use of Hydrus as a standalone MIGS in patients with mild to moderate open-angle glaucoma who have already had cataract surgery. The company noted that outside
Apply for the WMF2027 Startup Competition! GET YOUR TICKET NOW BUY NOW Accedi Registrati PROGRAM TRAINING Complete Program Stages categories PREMIUM stages DISCOVER stages OPEN stages Speakers Moderators FULL TICKET MAINSTAGE Program The Event Francesca Albanese Mathew Knowles Guests The Final of Startup Competition MAINSTAGE TICKET EXPO AREA Discover the Expo Area Exhibitors Startups Thematic Districts The International Pavilions Side Events Dronesoccer EU Championship FAIR TICKET MUSIC FEST The Festival MAINSTAGE TICKET THE WMF PARTY WMF Official Party Short Guide and Edition Theme Short Gui … rgest international startup competition JUNE 24 · 25 · 26, 2026 / BOLOGNA FIERE Apply now for the next edition Apply Numbers of WMF 2025 Startup Competition 6 Finalist +73.000 Attendees 14 Challenges of the Future 1.500B Investment Portfolio 304B AUM 17.000 Funding Rounds 1.000 VC & Open Innovation Stakeholders +3.000 Startups & Investors +90 Countries 72.8B Total Participation in Deals Visit The Official Website THE CONTEXT WMF, a Certified International Fair , has been spre … ed worldwide. The call for the 2026 edition is now closed. Fill out the form to apply for the WMF 2027 Startup Competition! Read more THE OPPORTUNITIES From the Startup Competition call, 6 finalists will be selected to compete on the Mainstage for the overall prize pool. An additional 140 startups (10 for each "Challenge of the Future") will access the Startup Stage , where they will pitch to the audience, VCs, investors, and international representatives from leading incubat … eration programs, and strategic partnerships. In 2025: 2.6 Million (Total Value Prize). Attend training and industry panels : Thanks to the stages dedicated to open innovation, it is possible to update entrepreneurial and technological skills, learn best practices, and increase competitiveness. Participate in the WMF International Roadshow: The international project that accompanies the best Italian startups abroad to major industry events. Access Saudi Makes Future (Riyadh – … ious editions The call for the 2026 edition is now closed. Fill out the form to apply for the WMF 2027 Startup Competition! Read more Timeline Sept. 11th 2025 Opening March 12th 2026 First Phase Closing April 16th 2026 Second Phase Closing From April 29th 2026 Feedback Challenges / Industries During the application phase, each startup is required
%PDF-1.7 %���� 1224 0 obj > endobj xref 1224 49 0000000016 00000 n 0000003069 00000 n 0000003204 00000 n 0000004408 00000 n 0000004523 00000 n 0000004562 00000 n 0000008778 00000 n 0000012532 00000 n 0000016012 00000 n 0000019186 00000 n 0000022825 00000 n 0000026474 00000 n 0000026966 00000 n 0000027777 00000 n 0000027902 00000 n 0000028212 00000 n 0000028685 00000 n 0000028944 00000 n 0000029640 00000 n 0000029753 00000 n 0000030024 00000 n 0000033843 00000 n 0000034122 00000 n 0000038246 00000 n 0000038360 00000 n 0000038459 00000 n 0000038535 00000 n 0000052598 00000 n 0000055248 00000 n 0 … y 8-9, 2020 | | Singapore Singapore WORLD WORLD CORNEA CORNEA CONGRESS CONGRESS application/pdf WCCVIII Logo uuid:55eac0ff-8537-3d4d-a9e3-62c9d55d7654 xmp.did:eb7d7dcb-31cc-4327-b038-266298b4da21 xmp.did:e4019234-b27e-481c-bfc8-ec88dca593d0 proof:pdf created xmp.iid:e4019234-b27e-481c-bfc8-ec88dca593d0 2016-02-01T16:12:21-05:00 Adobe Photoshop CC 2015 (Macintosh) saved xmp.iid:3b51ce79-b542-4eda-9738-44d2054c46cd 2016-02-01T17:13:35-05:00 Adobe Photoshop CC 2015 (Macintosh) / … 018-03-12T15:44:18-04:00 Adobe Illustrator CC 22.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:eb7d7dcb-31cc-4327-b038-266298b4da21 2022-08-14T16:04:15-06:00 Adobe Illustrator 26.4 (Macintosh) / x … ) 2020-01-13T15:57:25-05:00 2020-01-13T15:57:25-05:00 2020-01-13T15:57:25-05:00 application/postscript CS Logo 2013-corrected Susan Steury 4 U.S. Web Coated (SWOP) v2 Advancing the treatment of corneal disease Advancing the treatment of corneal disease Layer 8 Cornea Society Cornea Society Advancing the treatment of corneal disease Advancing the treatment of corneal disease Layer 8 copy Cornea Society copy 2 Cornea Society Layer 3 Cornea Society Cornea Society Cornea Society … 0BF7 2012-10-10T09:10:37-04:00 Adobe Photoshop CS6 (Macintosh) / converted from application/vnd.adobe.photoshop to image/epsf derived converted from application/vnd.adobe.photoshop to image/epsf saved xmp.iid:0580117407206811822AC8FD208F0BF7 2012-10-10T09:10:37-04:00 Adobe Photoshop CS6 (Macintosh) / saved xmp.iid:0280117407206811822AF059B7FDE674
EssexBio ABOUT US NEWS INVESTOR RELATIONS 简 繁 EN ABOUT US NEWS INVESTOR RELATIONS 简 繁 EN 简 繁 EN COMPANY NEWS s" data-wow-duration="1.5s"> Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance s" data-wow-duration="1.5s"> 2024.08.26 Related news Study Primary Endpoint Met in AURA-2, a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases 2026-06-16 Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance 2026-03-23 Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to H … tum in Regulatory Milestones 2025-08-26 NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration. 2025-08-13 Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China 2025-07-24 Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases 2025-04-02 Essex Bio-Technology (1061.HK) 2024 Ann … HK$1,637.7 million 2022-03-22 Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value 2021-12-20 First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O) 2021-11-10 Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021) 2021-10- … chnology Announces Upcoming Presentation at ARVO 2021 Annual Meeting 2021-04-30 Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia 2021-04-20 Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China 2021-04-07 Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD 2021-03-19 Essex Bio-Technology Announces 2020 F … wth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress Award 2019-01-10 Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics 2018-10-30 Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phas
http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember http://fasb.org/us-gaap/2021-01-31#ProductMember 45273231 1.91 0 0 75996732 76731940 0001393434 --12-31 2021 FY false true false 0 0 0 P7Y 18939 P3Y 0001393434 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2021-12-31 0001393434 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-12-31 0001393434 us-gaap:CommonStockMember us-gaap:O … eding 12 months (or for such shorter period that the registrant was required to submit such files).     ⌧    Yes      ◻   No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” ̶ … ur clinical trials and commercial use; ● the timing of and our ability to submit applications and obtain and maintain regulatory approvals for DEXTENZA, and other product candidates; ● our estimates regarding future revenue; expenses; the sufficiency of our cash resources; our ability to fund our operating expenses, debt service obligations and capital expenditure requirements; and our needs for additional financing; ● our plans to raise additional capital, … ment of post-surgical ocular inflammation and pain. The FDA approved a new drug application, or NDA, for DEXTENZA for the treatment of post-surgical ocular pain in November 2018 and approved a supplemental new drug application, or sNDA, for DEXTENZA for the treatment of post-surgical ocular inflammation in June 2019. In July 2019, we commercially launched DEXTENZA in the United States. DEXTENZA is the first FDA-approved, physician-administered intracanalicular insert deliveri … l range from the low teens to low twenty percent range. In return, we agreed to grant AffaMed exclusive rights to develop and commercialize DEXTENZA for the treatment of post-surgical inflammation and pain following ophthalmic surgery and ocular itching in patients with allergic conjunctivitis, and OTX-TIC for the reduction of elevated intraocula
From concept to capital: Venture-built Tulum Energy secures $27 million John Smith --> News #15-June 2026 #14-November 2025 #12-March 2025 #11-November 2024 #10-May 2024 #9-December 2023 #8-August 2023 #7-April 2023 #6-November 2022 #5-May 2022 #4-March 2022 #3-November 2021 #2-August 2021 #1-April 2021 Resources All Resources Videos Podcasts Papers EN EN ES All News #13-July 2025 Turquoise hydrogen From concept to capital: Venture-built Tulum Energy secures $27 million The recent seed round marks a milestone in the company's development journey, following its operational autonomy from it … nd. The investment was led by CDP Venture Capital (through its Green Transition Fund) and TDK Ventures, with contributions from MITO Technology (via MITO Tech Ventures), Doral Energy Tech Ventures, and TechEnergy Ventures (TEV), the corporate venture capital arm of the Techint Group. A revolutionary approach to a well-known process Tulum Energy was launched as a partnership between TEV and Tenova, a leading company in the provision of hydrogen-ready Direct Reduced Iron (DRI) … rs in the industry. CDP Venture Capital, which manages Italy's Green Transition Fund, is committed to supporting Tulum's Milan-based R&D hub by leveraging the Italian manufacturing supply chain. TDK Ventures, the VC arm of Japanese electronics giant TDK, contributed its global technology network to accelerate commercialization, while MITO and Doral Energy Tech Ventures added institutional depth. Given the project's growth ambitions and the capital required to de-risk and
Mitotech - 2026 Company Profile, Team & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates an
Henderson - Home Skip to main content Home News Sports Business Features Opinion Courier & Press Obituaries eNewspaper Crosswords Comics Newsletters For Subscribers Contributor Content Experts offer tips to help veterans with PTSD on July 4 The good news is there are things that can be done to better accommodate veterans on a day we celebrate independence. 5 ways to keep your pets calm during Fourth of July fireworks Here are 6 things to do in the Evansville area this weekend Powerball winning numbers, June 24, 2026: Lottery drawing results Lottery Trump touts US as 'hottest country' at Great
2026 Bio Europe Spring Attendee | LSX Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Fundraising & Investment 7-8 April 2027 - Main days, Lyon, France 6 April 2027 - Pre-day forums (Life Science Companies only) Home home Biotech expan … s (Guangzhou) Ltd. Choose Paris Region Chordia Therapeutics Inc. Chugai Venture Fund, LLC Chugai Venture Fund, LLC CIC bioGUNE Cilcare Cilcare Claris Ventures Claris Ventures Clayton Biotechnologies, Inc. Clinigen Clinigen Clinigen CNS Pharmaceuticals COCOON BIOSCIENCES Cogitars UK Colab Accelbio Colab Accelbio Colab Accelbio Complement Therapeutics Confo Therapeutics Confo Therapeutics Contera Pharma A/S Contera Pharma A/S CONVEYXO CorriXR Therapeutics CorriXR Therapeutics C … t University Ghent University Ghent University Ghent University GIBF Investment Fund GIBF Investment Fund GIP GENOPOLE GlobalData HealthCare GlobalData HealthCare GlobalData HealthCare GlycoNex GlycoTherapeutics GlycoTherapeutics Gnosis SpA Golgi Neurosciences Golgi Neurosciences Gordian Biotechnology Granzer Regulatory Consulting & Services GmbH Great Bay Bio Limited Greater Geneva Bern area GreenPine Pharma Group Co., Ltd. GreenPine Pharma Group Co., Ltd. Grünenthal Gmb … ents Hyloris Developments HyQure BioTech Co., Ltd HYUNDAI PHARM i&i Biotech Fund I SCSp i&i Biotech Fund I SCSp i&i Prague, s.r.o. i&i Prague, s.r.o. Icosagen Cell Factory OÜ Icosagen Cell Factory OÜ iDEL Therapeutics GmbH iDEL Therapeutics GmbH Idevax IDR Ie Sung International IEUM VALUE CREATOR INC. IGA Technology Services Srl IGES Institut Ignota Labs Ikarovec Limited Ikarovec Limited IMK IC Health Intelligence Immunethep ImmunoDesigners Co., Ltd. ImmunoFor
Obiettivo innovare il settore Cleantech: Iren investe nel fondo Mito Tech Ventures per identificare e adottare le migliori tecnologie green --> Skip to: Corporate Corporate I Siti del Gruppo Iren Iren Luce Gas e Servizi Ireti Eduiren Iren Collabora Iren Storia TRM Proposte di Sponsorizzazione ASM Vercelli AMIAT ACAM Ambiente ACAM Acque Atena Luce e Gas SEV Salerno Media Education Fornitori Carriere Trasparenza Arera Assistenza Logout IT EN Chi siamo I nostri servizi Sostenibilità Innovazione e ricerca Investitori Governance EveryDay Chi siamo I nostri servizi Sostenibilità Innovazione e ricerc
OIS Dry Eye Innovation Showcase 2021 | Ophthalmology Innovation Source Skip to content Follow our social pages & join our growing community Linkedin Youtube X-twitter Menu HOME EVENTS OIS Retina – July 14, 2026 OIS Ignite – March 11, 2027 OIS XVI – March 12-13, 2027 PAST EVENTS PODCASTS SPONSORSHIP VIEW ALL VIDEOS AGENDA | MARCH 11 1:00 - 1:15 PM Welcome and Dry Eye Overview Presented By: Paul Karpecki, OD, FAAO , Associate Professor - UPike College of Optometry/Kentucky Eye Institute 1:15 - 1:25 PM Dry Eye Market - Insights From Rx Presented By: Donald Fishbein , President -
Five biotech companies making waves in Luxembourg Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector Ap
Belluzzo International Partners advises IREN on its participation in the Mito Tech Ventures Fund - Belluzzo International Partners Italy UK Switzerland Singapore United Arab Emirates Global Search Contacts Work with us Register ITA ENG Who we are What we do What we think Who we work for Why Bee Belluzzo Our Firm Our Professionals Our values Our Brochure Our Corporate Video Awards Press ADVISORY & LITIGATION Trusts and Estate Planning Extraordinary Transactions Business, Corporate and M&A Domestic and International Taxation Tax Litigation Immigration & Relocation Legal Advice & … ernational Partners advises IREN on its participation in the Mito Tech Ventures Fund Oct 22 , 2024 Belluzzo International Partners advises IREN on its participation in the Mito Tech Ventures Fund IREN , the Italian multi-utility company that, through Iren UP, the Corporate Venture Capital programme, supports green start-up projects from clean technologies to the circular economy, has become one of the financiers of the Mito Tech Ventures Fund , a Venture Capital fund that wil
Safe Nuclear Energy Redefines AI Infrastructure and Geopolitics | Alberto Ricci posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Arendt for the first closing of MITO Tech Ventures! - Arendt Main navigation menu Go to search Main content Footer Arendt Go to home page Open the menu Close the menu Our People Careers Events Arendt & Art News & Insights Back to menu Back to menu News & Insights Our experts decipher the latest news for you and provide a clear and transparent analysis on topics related to your area of interest. Hot topics & Products News Laws & Regulations Videos Spotlight ESG & Sustainability Artificial Intelligence solutions Asset management regulatory solutions Remuneration solution … port Managed Services ESG AML/CFT services Investor services Corporate Services Fund Administration Services Governance Services Depositary Services Operational AML & Compliance services Tax Compliance Services Third Party AIFM Services Industries Back to menu Back to menu Industries Discover our customised services. Based on your profile and the industry in which you work, find here the full list of services that Arendt can provide. Banking, Finance & Insurance Navig … f public sector bodies Private Debt Specialist expertise for the expanding Debt Fund Market Real Estate At the heart of Luxembourg’s real estate investment growth Infrastructure Support across the infrastructure investment lifecycle Arendt Institute Back to menu Back to menu Arendt Institute Find a comprehensive learning solutions with a specific focus on legal, regulatory and tax matters, and also designs and delivers bespoke training sessions, specific workshops and coachin … cessful first closing of the MITO Tech Ventures, an art. 9 SFDR venture capital fund focused on climate tech investments. Arendt & Medernach oversaw the legal structuring of the fund and led the negotiations leading up to the first closing. The team, composed of Pierre Beissel, Giuseppe Di Gesù, Elettra Vercella-Baglione, Michele Messina and Matteo Davide Behboo collaborated with Orsingher Ortu – Avvocati Associati, which handled the Italian legal and regulatory aspects o … ios Georgiadis – has played a key role in advising on and structuring the Fund’s ESG methodology. Arendt Investor Services will provide comprehensive support as the Fund’s Administrative Agent, Registrar Agent, and Depositary, with a team composed by Sylvaine Fossen, Quentin Gillois and Francesca Scavino. AManco team, composed by Gaël
Instagram Instagram Log In Sign Up Close Never miss a post from tradedvc Sign up for Instagram to stay in the loop. Sign up Log in tradedvc Verified • Follow Luxembourg, Luxembourg More options tradedvc Verified 50w Tulum Energy, led by CEO Massimiliano Pieri, has raised an oversubscribed $27 million seed round to commercialize a rediscovered methane pyrolysis technology that splits methane into pure hydrogen and solid carbon without CO₂ emissions. Backed by TDK Ventures, CDP Venture Capital, Doral Energy-Tech Ventures, MITO Tech Ventures, and TechEnergy Ventures, the company plans to use the
%PDF-1.6 %���� 1728 0 obj >stream h��[ێ$5���ڗ�%$�òB�V �$4Z��B� 1�����HG��=U]���*W?�؝�Llj�ö���&���x�)M>N!��S�vJ4Y���d�Ӕ�d#����>O�'g��_q�&���!O '0��{�x����� ���[7yr ��IMF?e���G�8t�DV^���1��i�1�0&�����c0>���x ^���|'x���$OA��N���4E7�JS��'�L1FF�O1ˤ)N�X�$��k@/�0� (���d�,�c��l���Ô 8d #a��SN ���� L��Z� вs�ɦ� bp�(G 耟B�L�1�#�`���3�ы�3�e��q 68�8� �>�W懄/ Z��& ( �����Ƌ��>����Ϻ�(���+I$���Ev6�����y}�����E�_�Y $����y!e�σM6�(�,�"oAK |˃�c CP!�Y~s�͏b(�� �������|{�a������ ?���?��k2�/������nɋ�_#�i�jOb�v! ҮxM�sӮx��jW�N�����o������7������� �^����/��}��O�ݿ�^���R^�+� … 23-06-05T14:34:27+02:00 macOS Version 13.4 (assemblage 22F66) Quartz PDFContext application/pdf Microsoft Word - Rapport Annuel 2022_20230428_FINAL_sans les comptes_Trad_EN_US_230605.docx uuid:19811003-0394-a640-94df-f200aa36230d uuid:3b1e14b2-97fe-8340-b3a2-86366d190ead endstream endobj 1077 0 obj >stream H��UmO�0 ��_a�[�֜�8i*!�qۤ���*�L�t�ı���N�r��$�C�Km����N�KC��#����ȰX�����к��ʬk;��Ņ�w��yo�E ����a�7���OK�#��Un�vB*���-K�ʱK �N@V'��!�n�` �� endstream endobj 1078 0 … 23-06-05T14:36:31+02:00 macOS Version 13.4 (assemblage 22F66) Quartz PDFContext application/pdf Microsoft Word - Rapport Annuel 2022_20230428_FINAL_sans les comptes_Trad_EN_US_230605.docx uuid:19811003-0394-a640-94df-f200aa36230d uuid:71f9ea6f-83cb-0244-b98f-c1ffb0cedf5b endstream endobj 1733 0 obj > endobj 1735 0 obj >stream H��UmK�@���b�o�m�f�7 B�Z((M�-RγZ Z��u2ٙ]Mg��o�pu"l�2��{ZD�� �tU������ a� >stream H�\��j�0 ��~ �Cq�u� �c��ڱl��JfXl�8��}�t0� ?�?�K�ܼ6�%� L� z� … 23-06-05T14:39:35+02:00 macOS Version 13.4 (assemblage 22F66) Quartz PDFContext application/pdf Microsoft Word - Rapport Annuel 2022_20230428_FINAL_sans les comptes_Trad_EN_US_230605.docx uuid:19811003-0394-a640-94df-f200aa36230d uuid:cd530943-fdc7-a744-ae5d-3f90f6fa7d11 endstream endobj 1122 0 obj > endobj 1124 0 obj > endobj 1543 0 obj >stream x��1 �Om �@a�� 0`�� 0`�� 0`�� 0`�� 0`���-� endstream endobj 1544 0 obj >stream x��1 �Om �@a�� 0`� … 23-06-05T15:12:18+02:00 macOS Version 13.4 (assemblage 22F66) Quartz PDFContext application/pdf Microsoft Word - Rapport Annuel 2022_20230428_FINAL_sans les comptes_Trad_EN_US_230605.docx uuid:19811003-0394-a640-94df-f200aa36230d uuid:226d6310-7eb2-4801-8547-8891750d6733 endstream endobj 2120 0 obj > endobj 2121 0 obj >stream H��U�N�0}�WzKh� ��
MITO Technology - Portale per startup e venture capital Vai al contenuto Mondo Startup Mondo Venture Venture Capital Corporate Venture Capital Incentivi e servizi Business Angel Equity Crowdfunding Incubatori e acceleratori Startup Competition Altri soggetti Eventi Video Glossario Progetto Test di autovalutazione Mondo Startup Mondo Venture Venture Capital Corporate Venture Capital Incentivi e servizi Business Angel Equity Crowdfunding Incubatori e acceleratori Startup Competition Altri soggetti Eventi Video Glossario Progetto Test di autovalutazione Test di autovalutazione Home / Mondo Ventur … d began advising Progress Tech Transfer (now MITO Tech Transfer) — the first VC fund in Italy entirely focused on sustainability technologies. Building on the success of the first, in 2024 we launched a more ambitious initiative: MITO Tech Ventures, one of the first early-stage climate tech funds in Europe compliant with Article 9 of the SFDR regulation. Both funds — MITO Tech Transfer and MITO Tech Ventures — are RAIFs (Reserved Alternative Investment Funds) under the laws o
Mitotech S.A. Announces the Initiation of Phase II Clinical Trial in Dry Eye Patients Utilizing the Controlled Adverse Environment Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia All Photos All Videos Busine … ndent U.S. and European laboratories to support SkQ1 development. Company’s IND application for SkQ1 was approved in 2013. Natalia Perekhvatova, Mitotech, http://www.mitotechpharma.com, +1 6174755167, [email protected] × Modal title Contact PRWeb 11AM ET Sunday – 8PM ET Friday Contact Us Contact Us --> About PRWeb About PRWeb Partners Partnership Programs Editorial Guidelines Resources Why PRWeb Why PRWeb How It Works Who Uses It Pricing Accounts Create a Free Acco … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc.
%PDF-1.5 %���� 1084 0 obj > endobj 1197 0 obj >/Filter/FlateDecode/ID[ ]/Index[1084 222]/Info 1083 0 R/Length 364/Prev 5438937/Root 1085 0 R/Size 1306/Type/XRef/W[1 3 1]>>stream h����+Dq����\3e�!6 �I�Lٱ �X��$��Ȃ�dC�x�XX�ң�P� �(Y�$;��|��YZX��������sϽֈDĊU�S�+5 S۪mQM��1�3jaZu�Ȕ� ���$�qw�>t��j"�Ff�����2X�H �^�k=M���]5���%�Gev#�7���nc��f�ح��@]f�����yfp��igcמn���)��}�Ub6o7ɤ�.� {�l�wMkֻg2 L�s�����4V���.1:l��L�u� �|h���Ƒ-��S��?!�@7���)�:\ᛯ_�$&5.z�|�k$xɟ#&g���~�O��"��? n�?� endstream endobj startxref 0 %%EOF 1305 0 obj >stream hޤ�_lSU ǿ��v-�Mwo{�� ^Z�0l���D�0'$&t�@ f��E����� �lZ … ⬊YŬ�5�&�3��⊹"fgEΊ�9+vV��G��f M>�}4�h����G���8�!�O��o�|���B�6ƫ�G�� >stream application/postscript 21640 - Mitochondria Targeted Therapeutics logo_NEW Daniel Elliott 2021-10-12T13:56:59+01:00 2021-10-12T13:56:59+01:00 2021-10-12T13:56:59+01:00 Adobe Illustrator 25.2 (Macintosh) xmp.iid:a381136a-f33c-4861-bce5-53a1a70e200f xmp.did:a381136a-f33c-4861-bce5-53a1a70e200f uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9c21ad0e-4af9-4448-b973-8db87d0ef907 xmp.did:9c21ad … 610890 2020-11-26T17:40:54Z Adobe Illustrator 24.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4eed2328-5be5-40b8-b3fa-160472aa31c3 2020-12-14T11:34:53Z Adobe Illustrator 25.0 (Macintosh) / saved xmp.iid:ebf93fd6-38ad-469f-98ed-33d16b216654 2021-10-12T09:20:47+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:9c21ad0e-4af9-4448-b973-8db8 … 7 2021-10-12T13:55:01+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:a381136a-f33c-4861-bce5-53a1a70e200f 2021-10-12T13:56:59+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator Print Adobe Illustrator Adobe PDF library 15.00 1 True False 444.762974 201.626845 Millimeters NexaLight Nexa Light Regular Open Type Version 1.000 Fal … ƽ�;���M���P���+����9ę� T6L�wr,�~ ��f endstream endobj 1147 0 obj >stream application/postscript Print Daniel Elliott 2017-06-21T21:22:05+01:00 2017-06-21T21:22:05+01:00 2017-06-21T21:22:04+01:00 Adobe Illustrator CC 2015 (Macintosh) xmp.iid:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 xmp.did:6fd5c0ba-886c-4847-a42f-d9f2d2a03e85 uuid:5D20892493BFD
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Home - World Mitochondria Society The Future of Medicine will come through Mitochondria We are excited to invite you to the 17th World Mitochondria Scoiety's Annual Meeting, happening from October 21–23, 2026, in Berlin. This annual event brings together top experts in mitochondrial research and medicine to share new discoveries and ideas in mitochondrial therapy, gene treatment, and mitochondrial transplantation. READ MORE ... Metabolic effects of Cimicfuga racemosa extract on mitochondria and implications for the resistance against oxidative cell death and longevity Prof. Carsten Culmsee, ac … ntific career, Vladimir Skulachev dedicated himself to his project on practical application of penetrating ions. This ambitious endeavor focuses on developing new pharmaceuticals based on mitochondria-targeted antioxidants of the SkQ class. Mitotech's leading compound, SkQ1, is currently undergoing extensive development for different indications and in various pharmaceutical forms, including eye drop formulations (which have reached the third stage of clinical trials in the U … hondria 2023 to learn more about Dr. Murgia's exciting talk. You can submit a related abstract here. Targeting Mitochondria 2023 Congress October 11-13, 2023 - Berlin, Germany Mitochondria Organelle Transplantation for Neurological Diseases & Aging Dr. Mark S. Kindy from the University of South Florida, USA, will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "Mitochondria Organelle Transplantation for Neurological Diseases and A … ondrial society as a formidable platform offered by transplant medicine for the application of mitochondria-based technologies Join Targeting Mitochondria 2023 to learn more about Dr. Orlando's exciting talk. Read more about Dr. Orlando's latest promising findings. Targeting Mitochondria 2023 Congress October 11-13, 2023 - Berlin, Germany Targeting MCJ/DnaJC15 to modulate mitochondrial respiration in disease Dr. Mercedes Rincon, University of Colorado Anschutz School of Medic … Mitochondria 2023 to learn more about Dr. Rincon's exciting talk. You can submit a related abstract here. Targeting Mitochondria 2023 Congress October 11-13, 2023 - Berlin, Germany The Power of Epigenetics: The Patterns of mitoDNA Methylation Transmitted Across Generation Dr. Marc-André Sirard, Director of the Center for Research in Reprodu
%PDF-1.3 %��������� 3 0 obj > stream x�V�r 5}�W4���ʺ_x��!�*��Ex0[���]����=�%��.DZg $ I��>�n]� ]�V2��4�MI'�9t[�����Օ����_m�Mޤ�K�)����v2 �M�f�kz�^E2k! �A �n��a;��N�6 �ǘeP9S�2F� K3Q:g�UII�K;�ΰ��u �!�J�406E��I��-�_� Խx�������Oh u�&� ?���b'�Ђ- 8U�3���S�Q���i]�f820���Q\9s���x��o�p�@���Z�"(�vm�7�s c�㙥�n�QX��C���&�2$��ɡ�4�h�3N��_MOӀ/��͎����R� ?]P���o�C1���m��eז�r����l��J�2�*в�4QuFB�A`��f�8�`�����EM��5������zU2��""�p�W%��`s���4� ���*r��=�l��.�B�v� ,MG$�{��h�2�4��l 9��l����XO[:�x�yz�湻�bl�;ø� qO��I3&�� > endobj 4 0 obj > /Font > /XObject > >> endobj 7 0 obj > s … �O�8��N�%ŭϛ:�[ �W��e��|�*����u����1 �PK(| Մ�z��4���|��[���;k^��m��\�� W���RFP �Vu)�密R=O����Qdg�+��-�`�Y�� �y����� �.�v�=�m�k� �d� �E9 +���yV_f{���NJ�jB}F0G�æ�n sk �c>��x����YuC{ �� �:�o��d Ac���9�ݫ��lt������dz��ǚCaa I Y+0in�?�ݰ���2�� ��4�ɮj�_h,y��:���[b�n:�B�4:�� �CO�b��-��`�zWmw���5�)�q�)�[C��ck�f��� XZ՝�� s�4��^A &@��^����y OL��e ���cI���}k�>l֠[��V��ٚ��ya��b K�ac�c��]�,Z ��Nx�U5$�9C��v��i��@�5�i��Ww+�����Z���X���� ;��cԼ�V�!�eZ��Ƶ>mO��E�
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
干眼症新药美国3期研究获积极顶线数据 首页 关于我们 药促会简介 资质证书 协会章程 机构设置 协会领导 第十二届理事名单 第十二届监事名单 专业委员会 国际组织成员 IFPMA ICH 工作组专家 人才招聘 联系我们 党团工会 新闻聚焦 产业资讯 政策法规 研发追踪 医改专题 协会动态 通知公告 协会活动 国际交流 投资大会 其他会议 大事记 会员服务 会员单位 会员动态 入会申请 入会咨询 会员权益 会费标准 下载专区 EN 首页 关于我们 药促会简介 资质证书 协会章程 机构设置 协会领导 第十二届理事名单 第十二届监事名单 专业委员会 国际组织成员 IFPMA ICH 工作组专家 人才招聘 联系我们 党团工会 新闻聚焦 产业资讯 政策法规 研发追踪 医改专题 协会动态 通知公告 协会活动 国际交流 投资大会 其他会议 大事记 会员服务 会员单位 会员动态 入会申请 入会咨询 会员权益 会费标准 下载专区 产业资讯 政策法规 研发追踪 医改专题 干眼症新药美国3期研究获积极顶线数据 产业资讯 药明康德 2021-02-25 5589 2月24日，亿胜生物与Mitotech公司共同宣布VISTA-2研究的积极顶线数据——一项在美国开展的SkQ1治疗干眼症（DED）随机、双盲、安慰剂对照的多中心3期临床试验。根据新闻稿，Mitotech公司将于今年春季与美国FDA开展沟通，以确定
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's dise
Mitotech to present obesity treatment data at Boston conference | Mitotech posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
%PDF-1.7 %���� 1 0 obj >/Metadata 9890 0 R/ViewerPreferences 9891 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�nG}��D��_ÀmɊck}�� ��֫h��'/��[5∤� �����gاjNՙ��i��7�ѣ��g/��z�X ����\|x6�~�/|�S���{�?=�W����������c0�mw�*�6:K�ny��X�d��=�?@� �7�� ��Y;�~�k�y�9��' �/;o_���� �v ]��� r�x��� �����=�&YS�&8�4sc�i(�Ѡ��0;Z���͵F&wA�n��{~���qG�fy��%[uv�0���Z�):t��7]��hf}����"��t�n����t �d�C�JY� \���*�f�R��7T�W�]{w;� … O7]�5�����#�7�a�F��H�y� ���n_��������y����*?�ё�dQ��h*� ��{�#st�Ɋ� m��5�9�`*rFp��?}�؏b�᪩v1�����U� ّv+v�� �Xyʼn�"�\ov�o ��9������'���gW������ϯvE��8��Ub�4��_�ѳ ��_v��^�(ݾ�����Z����n�yPIVu P� ��y�* ���� :��I_��s���0% J��?w�VAh���J�#��B�@W\3f`rĠރd���Q�U�K�@����G�CG2� x��|uu@� �8I�}k!}�12�t����ώ����RؐX ���Bq �lի7 ݙ7.o��Q�� ���ϗ��2Wz27ffqTؠ�j8#� exkAFg�G�v,��-����N �W3v��N����[���O�g;:\c��cb�2ov��Ȏ�^LH���� ��'�xo�Zdr9��G*���-ؿN�h�#B��@�c����N� … �����y ~D�od��U������WF�������U�����>~�\��QώE]ez����&�!ƹ%vd��`]����u� �9�`)rFp���Bw�} ���w�gWZ&�� ��"�Q_�@L�}+�8����ͮ�Փ���[X��>}�l� U�B�Ǝ�V���33I�98�orV�s���Xu�)��B|�'IGݫ�j�'1���-ik S�e�"�h����CEZs���_@>^As}�c�?��o� #�uE����?z�^�װ�nwM���Mn (xk�ҭ_�N�c��9B�hP����aP@ �ڽè�(1��V�����T��p�mE� �*&�PC6 ��`7���F��OA|�E�YN�w�M��� �0��*��/�1�B�ge@ �Z���J�����e�� ��#>؉i?к4���o/s��Ӡ�S�*�Ad���i�ӓ^�'���������Z_��' ��Zݬ=!���a'@UhxvB� �͋C�m���81�S�]Y ܵث��
Mitotech - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs Int … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
--> Tau Group Secures €1.5 Million Investment from MITO Tech Ventures top of page Why Tretau Wire People Environment Tau Group Announces €1.5 Million Investment from MITO Tech Ventures to Expand Magnet Wire Production Oct 30, 2024 2 min read Updated: Jul 9, 2025 This investment enables Tau Group to expand its capacity to meet the rising demand for sustainable magnet wire solutions, supporting the global shift towards electrification. Turin, October 30, 2024 . Tau Group secures €1.5 million investment from MITO Tech Ventures, a venture capital firm focused on accelerating innovative technologie … P Venture Capital, and Santander Bank (through the Santander InnoEnergy Climate Fund) — will further accelerate the company's growth and expand its production capacity. Tau Group’s patented technologies enable sustainable and resource-efficient manufacturing, delivering the high performance essential for electrification. The company plays a pivotal role in the development of smaller, greener, and more powerful electric motors, transformers, and generators through its adv
MR.BUS YEOB DM - Five Stars AGR9066 #BasEkspresMalaysia... Facebook Log In MR.BUS YEOB DM's Post MR.BUS YEOB DM added a photo to the album: Five Stars June 16 at 6:40 PM · Shared with Public Five Stars AGR9066 #BasEkspresMalaysia #Mitotech All reactions: 33 1 share Like Comment
%PDF-1.7 %���� 1 0 obj >/Metadata 246 0 R/ViewerPreferences 247 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]_s�8�w�� f���C�'�R�r�d�;7us���C� [v\kK^E�$�~�I�H�ܩ�"�ݍ�F��$/~K^�|���_^'��E���U��,���$K4|��'����?��l��^}8?{�%������,aI�R���p�r�|x 9|�$��w7��� {(�R��f��n�X�zck������� ��L �-I��GX�Z�t�dGKvw�߷w�m�����,���i�&z�����H���$��d�أR?Y�B���� ������g�{ w��ֿ��+b������߬A��`K����Y����J�P�GQG��.�&-Z��Z����2� ��
MITO Tech Ventures raises €55 million for climatetech | Audacious Investor™️ posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … , Italy based MITO Technology recently first closed its new climatetech focused fund. 💸 €55 million at initial close for Mito Tech Ventures. The fund has a €90 million target and a hard-cap of €120 million. 💡 Investing in 25-30 innovative #climatetech start-ups with a focus on technologies reducing Co2 emissions in the fields of mobility, heavy industry, food production, and land use. 🌍 #Italy 📈 MITO Tech Ventures portfolio companies include i-Foria Italia and Tau Group . … unding #Europe #entrepreneurship #technology #innovation #tech #Milan #venture #fund Mito Tech Ventures, Mito Technology's new climatech fund https://www.startupbusiness.it/en/ 20 1 Comment Like Comment Share Copy LinkedIn Facebook X Francesco De Michelis 1y Report this comment Thank you for featuring our new fund and highlighting its activities! Just a quick note to clarify: the first closing of MITO Tech Ventures was at €55 million, not €50 million. We appreciate your suppo … nt, sign in Leonardo Baldi 8mo Report this post 💡 Odyssey Ventures gets a $75M fund to reduce the gap between European and US startups 🇪🇺🇺🇸European startups are facing a stubborn challenge: valuations that are 29% to 52% lower than their US counterparts. That’s where Odyssey Ventures steps in. Launched from stealth by Alastair Mitchell (ex-EQT Ventures) and Michelle Robson (ex-AP Ventures), Odyssey’s mission is to close the transatlantic valuation and funding gap, backin … ng News 65,369 followers 8mo Report this post 🚀 Odyssey Ventures launches $75M fund to bridge Europe–US startup valuation gap. Operating from London & San Francisco, their focus is on deep tech, manufacturing, chemicals, and neurotechnology, helping founders scale faster and globally. 🔗 Read more: https://lnkd.in/d_PDDVqz Alastair Mitchell
%PDF-1.6 %���� 10 0 obj > stream H���-h$Y������ +%Z �XQ1p�EÊq%V �(q0b �a\�B�'�J�8(9.Т�@�@�\}�W��J�Lnf?5�~�^����} �=�0} ���᧧�ʎ�"��&q�I�r�˧ ~��;��� ������p�m� � m�����w�T��5A֦���_�ٛ����n#$����cڭ�c�F�U�g��V����5�6 T+z �~h{7��n�����y� �� �+���~7����2 �I> m?�-�E���f? ���l{e=�����i\f���7�8=/��NG�x5�γ��]}��D�4kV�kY9[Wx�f~H��P6Ϭ}EA�̖�r�+ﱝ|��f�����U�. S�~�V��o��v���8 �jї|4hb)� �_�@y�l�[ۛ���?½���r�2��Ë����Nպ.F�� �r~�W���Q�v�e>�/�/�'��� ��w�z"�A�$����A��b��*y[�]��+��}g~ijq���+E/Vɳ�WV�z'i)T�Ü�R�p�U��W6����g�\�kE�A����h?�:�W bMm�~� j�V3}ę��W�g*�c����&��S��l�
%PDF-1.6 %���� 1367 0 obj > endobj 1379 0 obj >/Filter/FlateDecode/ID[ ]/Index[1367 82]/Info 1366 0 R/Length 85/Prev 4802387/Root 1368 0 R/Size 1449/Type/XRef/W[1 3 1]>>stream h�bbd```b`�� �A$� ��, �l ɴ DZĂU��I�� ���v0012�>�20ҏdGo� ���/��� endstream endobj startxref 0 %%EOF 1448 0 obj >stream h��Z}PS�ON�TH�]�!�{!�:R 1�| (6Q�(�$h�܄J�� vj�K����ҡ�J{��*j��ez��3��m]ge�{g�y��� ��;��� C�y�� ���=�3� !r3b#��Aq(�C ąq���d(�S����C,:�IO�G����"�F��~D"��2�?~�?��1��+�� �'u�\�.I�鴓@��C���/p��kdkׯݢJ��+��s��Z��B>0 �P#or �w��p6QHNv9�f�M_�!�Z�u���5i�y�Yt���˯�S�N��^� … 540 PC PROCESS 100.000000 CMYK 100.000000 55.000001 0.000000 55.000001 Document application/pdf AMF autorite des marches financiers proof:pdf uuid:e6c1b1dc-0ab0-4646-9e17-ba02aaa53ef4 uuid:4d065928-6a5a-cc43-a779-811f802912e5 Adobe PDF library 15.00 endstream endobj 7 0 obj >/ExtGState >/Properties >/Shading >>>/Subtype/Form/Type/XObject>>stream H��Wˎ 7��W�J%굍��f�H�d;�q��i����9$�zݛi'��A��m��D�M*� ��|X^}���ۻ���������}��k�ϙ}���>��(y������ͧX�� �{t C� T0?pK=���TKO����嫟ܫ … � 2�I�y|9GC7���=�|��%kN�s�������Q� �O�/ endstream endobj 118 0 obj >stream application/pdf LOGO LUMEVOQ lenadogene nolparvovec 2022-02-25T18:52:26+01:00 2022-02-25T18:52:26+01:00 2022-02-25T18:52:25+01:00 Adobe Illustrator 26.0 (Macintosh) uuid:441c876b-6cd7-634f-b850-7128dff45d8a xmp.did:5a1049f0-feb9-48fd-851f-e48e57cbe98f uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:e50c9b6b-6e78-bc44-aeac-f3184c4b87b5 xmp.did:a9b58ae1-99aa-4498-a1b9-102f91430311 uuid:5D208924 … sh) 2021-05-06T13:26:34+02:00 2021-05-06T13:26:34+02:00 Adobe PDF library 15.00 application/pdf GENSIGHT_URD_2020_VA_Chap_5.2.2 E-page 53 xmp.did:7285957b-2b8b-486d-909a-8320b26b367b uuid:35c88af8-bc5d-6449-8d9b-333a3951b40d uuid:0f205a53-820a-4f1d-a8fa-c4b9338d475b proof:pdf uuid:d9282ab4-69b4-41f3-b93f-8e8e1f190ac5 uuid:0f205a53-820a-4f1d-a8fa-c4b9338d475b uuid:0f205a53-820a-4f1d-a8fa-c4b9338d475b saved xmp.iid:7285957b-2b8b-486d-909a-8320b26b367b 2021-05-06T11:21:53+02:00 … sh) 2021-05-06T13:27:49+02:00 2021-05-06T13:27:49+02:00 Adobe PDF library 15.00 application/pdf GENSIGHT_URD_2020_VA_Chap_5.2.2 F-page55 1 False False 504.000000 504.000000 Points Helvetica Helvetica Regular TrueType 16.0d2e1 False Helvetica.ttc Helvetica-Bold Helvetica Bold TrueType 16.0d2e1 False Helvetica.ttc Helvetica-BoldOblique Helvetica Bo
Essex Biotechnology Secures Exclusive Rights in Mitotech’s lead candidate SkQ1 for Ophthalmology | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Essex Biotechnology Secures Exclusive Rights in Mitotech’s lead candidate SkQ1 for Ophthalmology 10/13/2022 Essex Bioinvestment Ltd, a wholly owned subsidiary of Essex Biotechnology, on 13 October 2022 secured a series of agreements related to patents and know-how for SkQ1, an active pharmaceutical ingredient, developed by Mitotech
Who Attended Targeting Mitochondria 2023? - World Mitochondria Society The Future of Medicine will come through Mitochondria We are excited to invite you to the 17th World Mitochondria Scoiety's Annual Meeting, happening from October 21–23, 2026, in Berlin. This annual event brings together top experts in mitochondrial research and medicine to share new discoveries and ideas in mitochondrial therapy, gene treatment, and mitochondrial transplantation. READ MORE ... Who Attended Targeting Mitochondria 2023? Industries Stealth Therapeutics (Sponsor) Mitotech (Sponsor) Anklam Extrakt GmbH Cellvie … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations 01/20/2017 Mitotech S.A., a Luxembourg-based clinical stage biotechnology company focused on developing treatments for age-related disorders such as Dry Eye Syndrome, announced that it received two U.S. patent
Mitotech LLC - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Mitotech LLC Holding Company | 2009 | Russia | en.skq-project.ru Holding Company | 2009 | Russia | en.skq-project.ru Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Eye Diseases Infectious Diseases Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Technology Platform Most used technologies in drug development No Data … ont payment and annual collaboration fee. In addition, Grifols has committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by Grifols and Selagine, including the clinical, manufacturing and regulatory activities required for FDA approval for dry eye disease indication. In February 2023, Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (N … ebruary 2023, Novaliq, announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation f … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Mitotech reports positive results from SkQ1 Phase II trial in patients with moderate to severe dry eye syndrome Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis &a … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × New eye drop formulation shows promise for dry eye disease
MitoWorld BETA Back to MitoWorld MitoWorld™ Welcome to the world of mitochondria Patients and Clinics Patient Orgs. Clinics MitoGuide Research and Industry Papers MitoPapers MitoRxiv Literature Highlights Collections Investigators Industry Funding Agencies Resources Working Groups Media and Events Events Media Books MitoMedia MitoBlog Mito-Cancer Conference Coverage MitoCast UMDF Beyond the Disease MitoNews MitoMap MitoGuide MitoPoster About Us Mission & Team Steering Committee Scientific Advisors Industry Advisors Medical Advisors Partners Services Downloads Topic Home / Mitotech M
World Wide Biotech Employers | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Luxembourg Biotech Employers Luxembourg has 5 employers in 5 locations. View the biotech employers in Luxembourg as a map Displaying 1 - 1 of 1 biotech employer locations Filter the data by: City Employer Business Area(s) Luxembourg view table | view map State / Province: Employer
Mitotech | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Mitotech Website: Mitotech Business Area(s) Small Molecules Mitochondria Description Mitotech S.A. is a Luxembourg-based single-molecule biotechnology company with a portfolio of novel drugs, based on mitochondria targeted antioxidants, for the treatment of age-related disorders undergo
16 Mitochondria Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Mitochondria 16 Employers in 18 locations Employers working on Mitochondria work in 20 other areas Displaying 1 - 15 of 20 related areas Show: 15 50 All Therapeutics (3) Rare Diseases (2) Small Molecules (2) Alzheimer's (1) Antisense RNA (1) Cancer Diagnostics (1) Cell
Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease 02/26/2021 Both VISTA-2 and VISTA-1 demonstrated significant impact of SkQ1 on clearing of Central Corneal Fluorescein Staining (CCFS) and improvement of Best Corrected Visual Acuity (BCVA) at day 28 (p<
Mito Tech Ventures, Mito Technology's new climatech fund Editorial Must Read Startup Kit Funding News Interviews Search Aa Size A A A Font Inter Georgia OpenDyslexic Reset OS default Light Dark IT EN Toggle navigation Search IT EN Close Editorial Funding News Interviews Startup Kit Scaleup Vc Voice Must Read Learn Legal Report Sponsored Video Vc Voice 29 Sep 2024 Mito Tech Ventures, Mito Technology’s new climatech fund The fund has an initial closing at EUR 50 million and intends to invest 25-30 mainly Italian companies Vc Voice 29 Sep 2024 Mito Tech Ventures, Mito Tec … Vc Voice 29 Sep 2024 Mito Tech Ventures, Mito Technology’s new climatech fund The fund has an initial closing at EUR 50 million and intends to invest 25-30 mainly Italian companies Author Editorial Staff Tags Cleantech investments italy startup venture capital Called Mito Tech Ventures, the new fund launched by Mito Technology is entirely dedicated to investing in start-ups that innovate in climate technology. In particular, the new fund launched by Mito Technology foc … avy industry, food production, and land use. Mito Tech Ventures is the first VC fund in Italy in line with Art. 9 of the SFDR regulation,’ Mito Technology announced in a note. ‘Moreover, 30% of the carried interest will be linked to the achievement of quantified environmental impact targets. This second fund, which renews the experience gained with the fund called Progress Tech Transfer, also has among its subscribers CDP Venture Capital and FEI (European Investme … also has among its subscribers CDP Venture Capital and FEI (European Investment Fund) with EUR 45 million subscribed, of which EUR 30 million from CDP Venture Capital and EUR 15 million from FEI. They are joined by companies in the environment and energy sectors, major professional pension funds and family offices . Mito Tech Ventures is looking for technologies with a level of technological maturity (TRL higher than 4) in the sustainability sector and early-stage start-ups ( … eed, series A), i.e. those that are still in the initial investment phase . The Fund offers companies still at an early stage not only the economic resources needed to develop the project, but also the managerial experience, skills, relationships and knowledge needed to transform the results of scientific and technological research into economic
#deeptech #energytransition #criticalmaterials #graphite #batteries #venturecapital | MITO Technology LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech English | 简体中文 | 繁體中文 | 한국어 | 日本語 Home | About us | Services | Partners | Events | Contact us | Login Thursday, June 25, 2026 Thursday, 13 October 2022, 22:40 HKT/SGT Share: Source: Essex Bio-Technology Limited Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech HONG KONG, Oct 13, 2022 - (ACN Newswire) - Essex Biotechnology Ltd (HKG: 1061) wishes to announce that wholly-owned subsidiary Essex Bioinvestmen … ssign, among others, all the rights of a list of inventions and patents, and to grant an exclusive, transferable and irrevocable Global license to Essex Bioinvestment, free from encumbrance, to use a list of patents owned by Mitotech relating to SkQ1 to develop, manufacture, sell and supply any therapeutic products or therapies applying to the eye and its adnexa, apply for and obtain Global regulatory approval for clinical trials, and obtain marketing authorisation in relatio
Home - Mito Technology About Mission Team Portfolio News ESG & Compliance Submit Now Our ambition is to capture innovation when it is still barely visible and turn it into a game-changer Our ambition is to capture innovation when it is still barely visible and turn it into a game-changer About MITO Technology is the advisor to venture capital funds aiming to achieve radical transformation in society for a more sustainable future. We were born as a platform to support public-to-private technology transfer. Over the last 15 years, we became progressively more hands-on participants of the inn … n 2018, we sponsored and advised MITO Tech Transfer - the first venture capital fund focused on technologies for sustainability. Following the good results of MITO Tech Transfer, in 2024 we started a new and more challenging journey with MITO Tech Ventures, one of the first early stage fund dedicated to climate tech compliant with art. 9 SFDR. Both MITO Tech Transfer and MITO Tech Ventures are reserved alternative investment fund (RAIF) under the laws of the Grand Duchy of Lu … e laws of the Grand Duchy of Luxembourg with an external alternative investment fund manager (AIFM). About MITO Technology is the advisor to venture capital funds aiming to achieve radical transformation in society for a more sustainable future. We were born as a platform to support public-to-private technology transfer. Over the last 15 years, we became progressively more hands-on participants of the innovation landscape in Europe, working with multinationals and SMEs, unive … n 2018, we sponsored and advised MITO Tech Transfer - the first venture capital fund focused on technologies for sustainability. Following the good results of MITO Tech Transfer, in 2024 we started a new and more challenging journey with MITO Tech Ventures, one of the first early stage fund dedicated to climate tech compliant with art. 9 SFDR. Both MITO Tech Transfer and MITO Tech Ventures are reserved alternative investment fund (RAIF) under the laws of the Grand Duchy of Lu … e laws of the Grand Duchy of Luxembourg with an external alternative investment fund manager (AIFM). Mission All our funds share common traits. We stay away from buzzword-investing and herd-wisdom and look constantly for sustainability-related technologies that have the potential to reshape the way supply chains, production and distribution syste
Go-GA | About Go-Lab Goes Africa Home (current) About About the Project Deliverables FAQ Partners Updates Blog Events Videos Gallery Newsletter Get in Touch Visit GoLabz MITO Technology Home Partners MITO Technology MITO Technology is a spin-off company of the Polytechnic University of Milan, the University of Padua and the University of Calabria; 3M Italia S.p.a. and the management team are also shareholders. MITO is a typical example of IP exploitation vehicle created by a group of universities not producing sufficient critical mass of exploitable IP needing a model of IP pooling for the man … from the European Union's Horizon 2020 research and innovation programme under grant agreement No 781012.
EssexBio ABOUT US NEWS INVESTOR RELATIONS 简 繁 EN ABOUT US NEWS INVESTOR RELATIONS 简 繁 EN 简 繁 EN COMPANY NEWS s" data-wow-duration="1.5s"> Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech s" data-wow-duration="1.5s"> 2022.10.13 Download Hong Kong, 13 Oct 2022 Essex Bio-Technology Limited (the “Company”, together with its subsidiaries, the “Group”) wishes to announce that Essex Bio-Investment Limited (“Essex Bio-Investment”), a wholly-owned subsidiary of the Group has on 13 October 2022 successf … ssign, among others, all the rights of a list of inventions and patents, and to grant an exclusive, transferable and irrevocable Global licence to Essex Bio-Investment, free from encumbrance, to use a list of patents owned by Mitotech relating to SkQ1 to develop, manufacture, sell and supply any therapeutic products or therapies applying to the eye and its adnexa (the “Products”), apply for and obtain Global regulatory approval for clinical trials, and obtain mark … tum in Regulatory Milestones 2025-08-26 NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration. 2025-08-13 Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China 2025-07-24 Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases 2025-04-02 Essex Bio-Technology (1061.HK) 2024 Ann … HK$1,637.7 million 2022-03-22 Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value 2021-12-20 First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O) 2021-11-10 Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021) 2021-10- … chnology Announces Upcoming Presentation at ARVO 2021 Annual Meeting 2021-04-30 Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia 2021-04-20 Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercialisation in China 2021-04-07 Essex-Biotechnology An
Mitotech Partners with Essex Bio-Technology for Late-stage Clinical Program in Dry Eye Disease Accessibility Statement Skip Navigation Why PRWeb How It Works Who Uses It Pricing Login GDPR Create a Free Account News Resources Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases Multimedia Gallery All Multimedia All Photos All Videos Business & Money Auto & Transporta … nical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will fund U.S. clinical program for Mitotech’s lead compound SkQ1 with approximately $17m allocated towards the first Phase 3 study starting as early as Fall 2018. This new partnership will allow us to jump-start late-stage SkQ1 development in the U.S. Post this “We are excited to have established a strategic partnership with Mitotech to co-develop SkQ1 on the global stage, through a Phase 3 clinical s … a Free Account Log in Contact Us Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Online Member Center ProfNet Cision Distribution Helpline 888-776-0942 Legal Site Map RSS Cookie Settings Copyright © 2025 Cision US Inc.
Mitotech S.A. - [LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab AMD Commits up to £2b to Accelerate AI in UK Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Lundbeck & Cradle Partner for AI-based Brain Disorder R&D AMD Silo AI and Delphyr AI PArtner for AI in Clinical Care Qiagen Announces Collaboration with Nvidia at Bio-IT World Scarlet Therapeutics Closes £3.2m Seed Round Led by Eos CellCentric Announces $220m Series D … 5b Tibeay Biosciences Raises €35m Round Led by Athos » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) ISSCR 2026 Montréal DxPx U.S. Conference 2026 Anaheim ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim IMSC 2026 Lyon European Conference on Computational … 2026 Marseille Biotech Showcase 2027 San Francisco » More Events! » Submit your Event! Management Appointments Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Bruker Appoints Qiagen CEO Thierry Bernard as Board Director Qiagen Appoints Mark Stevenson to Supervisory Board Pharming Group Appoints Kenneth Lynard as CFO Carmen Berger to Head Medica and Compamed Trade Fairs Julius Clinical Welcomes Bassem Saleh as CEO BIO Deutschland Elects Roland Sackers … ectorY Therapeutics Appoints Jessica Atkinson as CBO » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs CellCentric Announces $220m Series D Led by Venrock UCB to Acquire Candid Therapeutics for up $2.2b UCB Has Acquired the IMIDomics’ Patient Insight Business Coultreon’s $125m Series A Is Led by Sofinnova Investments CARB-X Awards Funding to AdJane to Advance Gonorrhea Vaccine UCB to Acquire Neurona T … os Adcendo Closes $75m Series C Led by Jeito Capital » More News! » Submit your News! Collaborations & Licensing Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Hansa Biopharma: €115m Licensing Agreement with SERB UCB Licenses Bispecific TCE Antibody from Antengene Bayer & Cradle Bio Announce 3-year Strategic Collaboration V
Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease 07/19/2018 Mitotech S.A., a Luxembourg-based clinical stage biotechnology company, announced entering a partnership agreement with Essex Bio-Investment for Phase 3 clinical program in Dry Eye Disease. Under the agreement Essex Bio-Invest … nical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will fund U.S. clinical program for Mitotech's lead compound SkQ1 with approximately $17m allocated towards the first Phase 3 study starting as early as Fall 2018. “We are excited to have established a strategic partnership with Mitotech to co- develop SkQ1 on the global stage, through a Phase 3 clinical study in the United States,” said Malcolm Ngiam, President of Essex Bio-Investment, “Mitotech recog
Mitochondria-focused drug development | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitochondria-focused drug development A New Approach: Targeted Mitochondrial Action Our groundbreaking drug candidates are designed to accumulate in mitochondria and to directly address mitochondrial function and increase energy expenditure. This allows low doses of the drug to regulate key biological processes involved in many serious diseases, such as rare mitochondrial disorders and meta
Welcome | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us The Mitochondria Company Empowering mitochondria to improve patients' lives Mitochondria , often referred to as the "powerhouses" of the cell, are central to a wide array of vital biological processes, most notably cellular respiration, which generates the majority of the cell's energy in the form of ATP. Given their critical role in energy production, mitochondrial dysfunction can have widespread and serious consequenc
Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease January 27, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Mitotech today announced that it will host a key opinion leader (KOL) webinar on Visomitin and its potential for the treatment of dry eye disease, on Fr … here. John D. Sheppard, M.D., M.M.Sc. is a Board Certified Ophthalmologist and fellowship-trained corneal eye surgeon. As the President of Virginia Eye Consultants, Dr. Sheppard oversees the organization's overall mission of providing a leading academic, clinical, and research center for excellence in ophthalmology. He is committed to providing the highest quality eye care solutions and is widely regarded as a leader in his field. George W. Ousler III is the Senior Vice Pres … octor of optometry degree from Indiana University and completed a Durrie Cornea Fellowship in Kansas City, in affiliation with the Pennsylvania College of Optometry. He currently serves as Director of Cornea and External Disease at Kentucky Eye Institute in Lexington KY and the Center for Sight in Carmel IN. He is also an Associate Professor at the Kentucky College of Optometry at the University of Pikeville and is the Medical Director for KEPLR Vision. About Mitotech S.A. Mi … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Ge … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome April 23, 2015 | 3 min read Twitter LinkedIn Facebook Email Print Luxembourg, April 23, 2015 / B3C newswire / -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company deve … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst " href="https://www.biospace.com/deals/lilly-astellas-circle-sangamo-assets-as-biotech-files-for-bankruptcy" > Bankruptcy Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy June 23, 2026 · 3 min read · Gabrie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
MITOTECH presents promising results in friedreich’s ataxia - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases MITOTECH presents promising results in friedreich’s ataxia September 17, 2024 | 1 min read Twitter LinkedIn Facebook Email Print September 17, 2024 London, UK Mitotech Ltd, a mitochondria-focused clinical-stage biotechnology company, presented new data for its mitochondria-targeted ferroptosis inhibitor i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Welcome | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us The Mitochondria Company Empowering mitochondria to improve patients' lives Mitochondria , often referred to as the "powerhouses" of the cell, are central to a wide array of vital biological processes, most notably cellular respiration, which generates the majority of the cell's energy in the form of ATP. Given their critical role in energy production, mitochondrial dysfunction can have widespread and serious consequenc
News | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us News and Events 06/30/2025 ADA 2025: Sensing a Shift in Obesity Care Industry 06/06/2025 Mitotech to present at Obesity Science and Innovation 2025 11/15/2024 Mitotech Presents New positive Animal Efficacy Data for SkQ1 in MASH Treatment at The 75th Liver Meeting 11/06/2024 Mitotech Unveils Promising New Obesity Treatment Data on SkQ1 at ObesityWeek 2024 09/17/2024 Mitotech Presents Promising Results in Friedreich’s Ataxia
Mitotech Presents New positive Animal Efficacy Data for SkQ1 in MASH Treatment at The 75th Liver Meeting | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech Presents New positive Animal Efficacy Data for SkQ1 in MASH Treatment at The 75th Liver Meeting 11/15/2024 Mitotech Ltd., a clinical-stage biotechnology company focused on developing mitochondria-based therapies, today announced the presentation of compelling new animal efficacy data on its investigational compound,
Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON 12/15/2021 The US Orphan Drug Designation would provide seven-year market exclusivity if Visomitin was approved for use in LHON. Mitotech S.A., a Luxembourg-based clinical-stage biotechnology company in ophthalmology, announced that the U.S. Food and Drug Administration (FDA) has granted … ear market exclusivity upon regulatory approval if received, exemption from FDA application fees and tax credits for qualified clinical trials. About Mitotech S.A. Mitotech S.A. is a Luxembourg-based late clinical stage biotechnology company developing drugs to treat the mitochondrial oxidative stress underlying predominantly age-related ophthalmology disorders. Mitotech’s products are based on novel small molecules that inhibit cardiolipin peroxidation within mitochondria. F
Mitotech - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners Tu … ylcholinesterase inhibitors antioxidants autoimmune diseases View Patents Chart Application Date Grant Date Title Related Topics Status 11/9/2023 9/3/2024 Crystalline form of antioxidant compound Acetylcholinesterase inhibitors, Water ice, Orthorhombic minerals, Monoclinic minerals, Crystallography Grant Application Date 11/9/2023 Grant Date 9/3/2024 Title Crystalline form of antioxidant compound Related Topics Acetylcholinesterase inhibitors, Water ice, Orthorhombic minerals … , Water ice, Orthorhombic minerals, Monoclinic minerals, Crystallography Status Grant Learn more by requesting a demo Latest Mitotech News Mitotech Presents Promising Results in Friedreich's Ataxia Sep 17, 2024 News provided by Share this article Mitotech logo Mitotech presented positive data showing protection of Friedreich's Ataxia fibroblasts from oxidative stress and ferroptosis with its leading compound SkQ1 as monotherapy and in combination with omaveloxolone.
Mitotech to present at Obesity Science and Innovation 2025 | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech to present at Obesity Science and Innovation 2025 06/06/2025 London, UK – June 6, 2025 – Mitotech Ltd., a clinical-stage biotechnology company focused on mitochondria-based therapies, will present new results in animal models of obesity for its investigational compound SkQ1 at Obesity Science & Innovation 2025 . The inaugural conference, held September 16-1
Mitotech Unveils Promising New OBESTITY TREATMENT Data on SkQ1 at ObesityWeek® 2024 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Mitotech Unveils Promising New OBESTITY TREATMENT Data on SkQ1 at ObesityWeek ® 2024 November 15, 2024 | 1 min read Twitter LinkedIn Facebook Email Print San Antonio, TX – November 6, 2024 – Mitotech Ltd., a clinical-stage biotechnology company focused on mitochondria-based therapies, presented compelling … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
I am proud to announce that Mitotech CSO Dr Maxim Skulachev will present our latest efficacy data at the 14th Targeting Mitochondria conference in Berlin. | Natalia Perekhvatova LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Re … ntific career, Vladimir Skulachev dedicated himself to his project on practical application of penetrating ions. This ambitious endeavor focuses on developing new pharmaceuticals based on mitochondria-targeted antioxidants of the SkQ class." Mitotech's leading compound, SkQ1, is currently undergoing extensive development for different indications and in various pharmaceutical forms, including eye drop formulations (which have reached the third stage of clinical trials in the
"> Interview: Natalia Perekhvatova - CEO, Mitotech, Luxembourg Search for: Sign in Register Reports Interviews Articles Legal & Regulatory Facts & Figures Op-eds Shop Thursday, June 25, 2026 Sign In Register Home Country Reports All Americas Asia-Pacific Europe Middle East & Africa Exclusive interviews All Latest Americas Asia-Pacific Europe Middle East & Africa Articles All Global Latest Legal & Regulatory All The Pharma Legal Handbook Regulatory, Pricing and Reimbursement Marketing, Manufacturing, Packaging and Labeling Preclinical and Clinical Trials Op-Eds & Contri
Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021 | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021 03/04/2021 Mitotech S.A., a Luxembourg-based clinical-stage biotechnology company, is proud to announce that its CEO, Natalia Perekhvatova, is invited to present at OIS Dry Eye Innovation Showcase 2021. The event will take place on Mar 11, 2021. Hope to see you
MITOTECH LTD persons with significant control - Find and update company information - GOV.UK Cookies on Companies House services We use some essential cookies to make our services work. We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Accept analytics cookies Reject analytics cookies View cookies You've accepted analytics cookies. You can change your cookie settings at any time. Hide this message You've rejected analytics cookies. You can change your cookie settings at any time. Hide this message Cookies on Companies House services
Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment 04/21/2014 Mitotech S.A., a Luxembourg-based clinical-stage biotechnology company today announced that it has initiated Phase II clinical trial of SkQ1 compound evaluati … ndent U.S. and European laboratories to support SkQ1 development. Company's IND application for SkQ1 was approved in 2013. © 2026 Mitotech Ltd - All Rights Reserved - Privacy Policy
MITOTECH LTD filing history - Find and update company information - GOV.UK Cookies on Companies House services We use some essential cookies to make our services work. We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Accept analytics cookies Reject analytics cookies View cookies You've accepted analytics cookies. You can change your cookie settings at any time. Hide this message You've rejected analytics cookies. You can change your cookie settings at any time. Hide this message Cookies on Companies House services We use cookies to
Mitotech CSO to present at Targeting Mitochondria 2023 Conference | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Mitotech CSO to present at Targeting Mitochondria 2023 Conference 09/21/2023 Mitotech Ltd, a clinical-stage biotechnology company, announced that its Chief Scientific Officer, Dr Maxim Skulachev, will give a presentation at the Targeting Mitochondria 2023 conference , taking place in October 2023 in Berlin, Germany. The conference is an annual event attracting ac
Mitotech CSO to Present Visomitin® Data in Dry Eye Disease and Glaucoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Mitotech CSO to Present Visomitin® Data in Dry Eye Disease and Glaucoma February 24, 2022 | 1 min read Twitter LinkedIn Facebook Email Print Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, announced that its Chief Scientific Officer, Dr Maxim Skulachev, will give a full presentation at the Mitocho … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Advances in the Development of Mitochondria-Targeted Pharmaceuticals - World Mitochondria Society Advances in the Development of Mitochondria-Targeted Pharmaceuticals Details Published on 06 September 2023 Dr. Maxim Skulachev, CSO at Mitotech (Israel) , who manages Mitotech's core scientific research, will share the latest advances in developing mitochondria targeting drugs during Targeting Mitochondria 2023 this October. In the last 15 years of his life and scientific career, Vladimir Skulachev dedicated himself to his project on practical application of penetrating ions. Thi … on at the 17th World Congress on Targeting Mitochondria... Read more Best Image Award 2025 Winners Announced We are thrilled to reveal the three winners of the Best Image in Mitochondria Research 2025! ... Read more Mitochondria & Organelle Crosstalk - Rethinking Organelle Crosstalk: Mitochondrial-Derived Vesicles in Peroxisome Biogenesis Presented by Dr. Ayumu Sugiura At the heart of cellular metabolism, mitochondria and peroxisomes play tightly interconnected rol … niversity of Groningen, Netherlands, for receiving the Best Poster Presentation Award at the 15th... Read more Gallbladder Mitochondrial Function as a Predictor of Liver Transplantation Outcomes Wins WMS Best Poster (2) The World Mitochondria Society is excited to announce that Danielius Umbrasas from the Lithuanian University of Health Sci... Read more Nominations for Best Mitochondria Image 2024 1. Never Tear Us Apart By Una Rastovic, The Roger Willi
Management Team | Mitotech × Home About Us Our Technology Management Team News & Events Contact Us MITO .tech About Us Our Technology Management Team News & Events Contact Us Management Team Mitotech’s management team has decades of experience in clinical trials, drug development, finance, biological research and start-up management. The multinational team brings a fresh perspective on how science and biomarker-driven clinical development can transform patients’ lives. CEO: Natalia Perekhvatova, MS, MBA Natalia Perekhvatova has been leading company’s evolution from a drug discovery s
Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON December 16, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company in ophthalmology, announced that the U.S. Food and Drug Administration has granted orp … ear market exclusivity upon regulatory approval if received, exemption from FDA application fees and tax credits for qualified clinical trials. About Mitotech S.A. Mitotech S.A. is a Luxembourg-based late clinical stage biotechnology company developing drugs to treat the mitochondrial oxidative stress underlying predominantly age-related ophthalmology disorders. Mitotech’s products are based on novel small molecules that inhibit cardiolipin peroxidation within mitochondria. F … sp; 3 min read · Heather McKenzie Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Manufacturing With onshoring ‘having a moment,’ Aquestive CEO shares lessons from 20 years of US manufacturing June 23, 2026 · 4 min read · Nick Paul Taylor BioSpace is the digital hub for life science news and jobs. We provide … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface | springermedicine.com The Role of SKQ1 (Visomitin) in Inflammation and Wound Healing of the Ocular Surface | springermedicine.com Skip to main content Menu Browse CME & eLearning Webinars & Videos Podcasts Clinical Trial Summaries Medical Journals Subscribe to our newsletters Key Specialties Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gyne